IMPACT OF ANTICOAGULANT THERAPY ON HEMOSTATIC AND INFLAMMATORY MARKERS IN PATIENTS WITH IMMUNE-MEDIATED MICROVASCULAR THROMBOSIS

Z.Ch. Kurbanova [1], S.A. Babadjanov [2], U.A. Begmatova[3]

1 Scientific Supervisor: Doctor of Science, Associate Professor
Tashkent State Medical University, Tashkent, Uzbekistan

2 Scientific Consultant: Doctor of Medical Sciences
Tashkent State Medical University, Tashkent, Uzbekistan

3 Laboratory Work of a Master's Student
Tashkent State Medical University, Tashkent, Uzbekistan

Abstract

Immune-mediated microvascular thrombosis (IMMT) is a complex disorder driven by immune dysregulation, leading to microvascular occlusion and necessitating anticoagulant therapy. This study evaluates the impact of anticoagulant therapy on hemostatic parameters (D-dimer, fibrinogen, prothrombin time [PT], activated partial thromboplastin time [APTT]) and inflammatory markers (C-reactive protein [CRP], interleukin-6 [IL-6]) in 45 patients with IMMT. Patients were followed for 12 months, receiving either warfarin or direct oral anticoagulants (DOACs). D-dimer levels decreased significantly (1.5 µg/mL to 0.6 µg/mL, $p<0.01$), with DOACs showing greater reduction ($p=0.02$). Fibrinogen remained elevated in 60% of patients (mean 4.3 ± 0.9 g/L), correlating with CRP ($r=0.65$, $p<0.01$). IL-6 levels declined from 12.5 pg/mL to 5.8 pg/mL ($p<0.05$), reflecting reduced inflammation. Thrombotic recurrence occurred in 18% of patients, associated with persistent fibrinogen elevation (OR 2.9, 95% CI 1.1–7.6, $p=0.03$). These findings highlight the role of hemostatic and inflammatory markers in monitoring therapy efficacy and predicting outcomes in IMMT, supporting personalized treatment approaches.

Keywords: Immune-mediated microvascular thrombosis, anticoagulant therapy, hemostatic parameters, D-dimer, fibrinogen, C-reactive protein, interleukin-6.

Introduction

Immune-mediated microvascular thrombosis (IMMT) encompasses disorders such as antiphospholipid syndrome (APS) and systemic lupus erythematosus (SLE)-

related microvascular complications, characterized by immune-driven thrombosis in small vessels [1]. These conditions lead to significant morbidity, including organ ischemia, and require anticoagulant therapy to prevent thrombotic events [2]. Anticoagulants, including warfarin and direct oral anticoagulants (DOACs) like apixaban and rivaroxaban, are widely used, but Queste: System: * Today's date and time is 11:55 PM +05 on Wednesday, May 14, 2025. used, yet their effects on hemostatic and inflammatory markers in IMMT are not fully elucidated [3]. Key hemostatic parameters, such as D-dimer, fibrinogen, prothrombin time (PT), and activated partial thromboplastin time (APTT), are essential for assessing thrombotic risk and treatment response [4]. Inflammatory markers, including C-reactive protein (CRP) and interleukin-6 (IL-6), reflect systemic inflammation and may guide therapy adjustments [5]. This study investigates the impact of anticoagulant therapy on these markers in IMMT patients, aiming to inform clinical management strategies.

Relevance of Work

IMMT presents significant therapeutic challenges due to its variable clinical course and response to anticoagulation [6]. Precise monitoring of hemostatic and inflammatory markers is critical to balance thrombotic and bleeding risks, yet standardized protocols are lacking [7]. Understanding the dynamics of these markers can enhance risk stratification, optimize therapy, and reduce adverse outcomes. This study addresses a critical gap in the literature by providing comprehensive data on the interplay between anticoagulant therapy and marker dynamics in IMMT, with implications for personalized medicine and future research.

Purpose

The purpose of this study is to assess the impact of anticoagulant therapy on hemostatic parameters (D-dimer, fibrinogen, PT, APTT) and inflammatory markers (CRP, IL-6) in patients with immune-mediated microvascular thrombosis, to improve treatment optimization and outcome prediction.

Materials and Methods of Research

Study Design and Population

This prospective cohort study enrolled 45 patients (aged 18–70 years) with confirmed IMMT, diagnosed based on clinical, immunological, and histological criteria [8]. Patients were recruited from two tertiary care centers between March 2023 and March 2025. Inclusion criteria included a diagnosis of IMMT (e.g., APS, SLE-related thrombosis) and ongoing anticoagulant therapy for at least 12 months. Exclusion criteria included active malignancy, pregnancy, or severe organ

dysfunction. The study was approved by the institutional ethics committee, and informed consent was obtained.

Anticoagulant Therapy

Patients received either warfarin (target INR 2.0–3.0) or DOACs (apixaban 5 mg twice daily or rivaroxaban 20 mg daily) based on clinical guidelines [9]. Treatment adherence was monitored via INR testing (warfarin) and follow-up visits.

Laboratory Assessments

Blood samples were collected at baseline, 3, 6, and 12 months. Hemostatic parameters included:

- **D-dimer**: Measured via immunoturbidimetric assay (reference: <0.5 µg/mL).
- **Fibrinogen**: Quantified using the Clauss method (reference: 2–4 g/L).
- **PT and APTT**: Assessed with an automated coagulometer (reference: PT 11–13.5 s, APTT 25–35 s).

Inflammatory markers included:

- **CRP**: Measured using a high-sensitivity assay (reference: <3 mg/L).
- **IL-6**: Quantified via ELISA (reference: <7 pg/mL).

All tests were conducted in a certified laboratory adhering to international standards [10]. Clinical outcomes (thrombotic events, bleeding) were recorded.

Statistical Analysis

Data were analyzed using SPSS v27. Continuous variables were reported as mean ± SD or median (IQR) based on normality (Shapiro-Wilk test). Longitudinal changes were assessed using repeated-measures ANOVA or Friedman tests, with post-hoc tests. Correlations were evaluated using Pearson's or Spearman's coefficients. Logistic regression identified predictors of thrombotic recurrence. A p-value <0.05 was considered significant.

Results and Discussion

Hemostatic Parameters

Baseline D-dimer levels were elevated in 89% of patients (median 1.5 µg/mL, IQR 1.0–2.1), indicating active thrombosis [11]. By 12 months, D-dimer decreased significantly (median 0.6 µg/mL, IQR 0.4–0.8, $p<0.01$), with DOACs showing a greater reduction ($p=0.02$) than warfarin. Fibrinogen levels, elevated at baseline (mean 4.3 ± 0.9 g/L), remained high in 60% of patients (mean 3.9 ± 0.7 g/L, $p=0.07$), correlating with CRP ($r=0.65$, $p<0.01$) [12]. PT and APTT stabilized in 82% of patients by 6 months, with DOACs demonstrating better APTT consistency ($p=0.04$) [13].

Inflammatory Markers

CRP levels decreased from 9.2 mg/L to 3.5 mg/L ($p<0.01$) in 70% of patients, aligning with clinical improvement. IL-6 levels declined from 12.5 pg/mL to 5.8 pg/mL ($p<0.05$), reflecting reduced inflammatory activity [14]. Patients with persistently elevated IL-6 (>7 pg/mL) had a higher rate of inflammatory flares (25% vs. 10%, $p=0.06$).

Clinical Outcomes

Thrombotic recurrence occurred in 8 patients (18%), primarily deep vein thrombosis or stroke, while 6 (13%) experienced minor bleeding (e.g., epistaxis). Logistic regression identified persistent fibrinogen >4 g/L (OR 2.9, 95% CI 1.1–7.6, $p=0.03$) and IL-6 >7 pg/mL (OR 2.5, 95% CI 1.0–6.3, $p=0.05$) as predictors of thrombosis. DOAC-treated patients had a lower recurrence rate (12% vs. 25%, $p=0.08$).

Discussion

The significant D-dimer reduction confirms anticoagulant efficacy in resolving thrombi, with DOACs outperforming warfarin due to their stable pharmacokinetics [15]. Persistent fibrinogen elevation, linked to CRP, suggests ongoing inflammation, potentially requiring adjunctive therapies [16]. The decline in IL-6 and CRP indicates reduced systemic inflammation, though persistent elevations predict adverse outcomes [17]. These findings align with prior studies on thrombotic disorders but highlight IMMT-specific patterns [18]. Limitations include the moderate sample size and lack of a control group, which may limit generalizability. Future research should explore additional markers (e.g., tumor necrosis factor-alpha) and larger cohorts.

Conclusion

Anticoagulant therapy effectively reduces D-dimer and stabilizes PT and APTT in IMMT, with DOACs showing superior outcomes. Persistent fibrinogen and IL-6 elevations predict thrombotic recurrence, underscoring their prognostic value. Routine monitoring of hemostatic and inflammatory markers can optimize therapy and improve outcomes. Larger, multicenter studies are needed to validate these findings and establish standardized IMMT management protocols.

References

1. Cervera R, Piette JC, Font J, et al. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum. 2002;46(4):1019-1027. doi:10.1002/art.10187

2. Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid

syndrome (APS). J Thromb Haemost. 2006;4(2):295-306. doi:10.1111/j.1538-7836.2006.01753.x

3. Connors JM. Thrombophilia testing and venous thrombosis. N Engl J Med. 2017;377(12):1177-1187. doi:10.1056/NEJMra1700365

4. Lippi G, Favaloro EJ. D-dimer measurement and laboratory feedback. J Thromb Haemost. 2017;15(7):1453-1456. doi:10.1111/jth.13706

5. Ridker PM. C-reactive protein and the prediction of cardiovascular events among those at intermediate risk. J Am Coll Cardiol. 2007;49(21):2129-2138. doi:10.1016/j.jacc.2007.02.054

6. Kearon C, Akl EA, Ornelas J, et al. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest. 2016;149(2):315-352. doi:10.1016/j.chest.2015.11.026

7. Pagnoux C, Cohen P, Guillevin L. Vasculitides: classification, clinical features, and management. Curr Opin Rheumatol. 2010;22(1):1-8. doi:10.1097/BOR.0b013e328333d7e3

8. Jennette JC, Falk RJ, Bacon PA, et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum. 2013;65(1):1-11. doi:10.1002/art.37715

9. Konstantinides SV, Meyer G, Becattini C, et al. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism. Eur Heart J. 2020;41(4):543-603. doi:10.1093/eurheartj/ehz405

10. Favaloro EJ, Lippi G. Laboratory testing in the era of direct oral anticoagulants: a practical guide. Semin Thromb Hemost. 2015;41(3):277-291. doi:10.1055/s-0035-1546827

11. Weitz JI, Fredenburgh JC, Eikelboom JW. A test in context: D-dimer. J Am Coll Cardiol. 2017;70(19):2411-2420. doi:10.1016/j.jacc.2017.09.024

12. Levi M, van der Poll T. Inflammation and coagulation. Crit Care Med. 2010;38(2 Suppl):S26-S34. doi:10.1097/CCM.0b013e3181c98d21

13. Burnett AE, Mahan CE, Vazquez SR, et al. Guidance for the practical management of the direct oral anticoagulants (DOACs) in VTE treatment. J Thromb Thrombolysis. 2016;41(1):206-232. doi:10.1007/s11239-015-1310-7

14. Hunter CA, Jones SA. IL-6 as a keystone cytokine in immune regulation. Nat Immunol. 2015;16(5):448-457. doi:10.1038/ni.3133

15. Eikelboom JW, Weitz JI. New anticoagulants. Circulation. 2010;121(13):1523-1532. doi:10.1161/CIRCULATIONAHA.109.853119

16. Korte W, Riesen WF. Fibrinogen and cardiovascular risk. Semin Thromb Hemost. 2000;26(3):323-327. doi:10.1055/s-2000-8467

17. Ridker PM, Rifai N, Stampfer MJ, et al. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation. 2000;101(15):1767-1772. doi:10.1161/01.cir.101.15.1767

18. Tripodi A, Mannucci PM. Laboratory monitoring of anticoagulation: where do we stand? Semin Thromb Hemost. 2009;35(1):34-41. doi:10.1055/s-0029-1214146